Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum MYND Life Sciences Inc C.MYND

Alternate Symbol(s):  MYNDF

MYND Life Sciences Inc. is a Canada-based medical biotech drug research and development company. The Company is focused on neuro-pharmaceutical drug development, diagnostics and vaccines. It is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio) pharmaceutical companies by molecular concepts for the applications of psilocybin... see more

CSE:MYND - Post Discussion

MYND Life Sciences Inc > Now Alzheimers and Dementia lanes!
View:
Post by SmallCapIntel on Jun 23, 2021 8:53am

Now Alzheimers and Dementia lanes!

Love  seeing these guys expand their psych medicine science into Alzheimer's disease and Dementia. Two incredibly sad things to happen to a human as they age. If we can find a solution to that...that would be so freaking massive
 
https://www.newswire.ca/news-releases/mynd-life-sciences-expands-intellectual-portfolio-to-target-alzheimer-s-disease-and-related-forms-of-dementia-with-chemical-subclasses-of-psilocybin-analogues-858428836.html
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities